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Chapter 27
Drug Users as Stakeholders in Drug 
Policy: Questions of Legitimacy and  
the Silencing of the Happy Drug User
Anna Ross
Calls for ‘evidence-based policy’ and greater community ‘partici-
pation’ are often heard in the drug policy field. Both movements 
are in different ways concerned with the same questions about how 
‘drug problems’ ought to be governed and the place of ‘expertise’ 
and ‘engagement’ in democratic societies. However, these calls rely 
on the assumption that knowledges, publics, expertise, and issues 
of concern are fixed and stable, waiting to be addressed or called to 
action, thus obscuring ontological questions about what ‘participa-
tion’ (be that lay or expert) may do or produce. There has been lim-
ited research in the drugs field that has taken ‘participation’ as an 
object of study in itself and through critical examination attempted 
to open up new possibilities for its remaking.
(Lancaster et al., 2018, p. 351)
Introduction
In 2014, I started a PhD in drugs policy at the University of Edinburgh. My inter-
est in the area was personal. As a woman (and now a mother) who uses drugs, and 
has done since the age of 14, I have been at the sharp end of drug policy decisions 
for 26 years. Throughout these years, I have experienced multiple drug-using 
communities and witnessed the impact criminal sanctions have on these commu-
nities. I have friends who have been imprisoned, stigmatised and died as a result 
of their drug use. I have internalised a deviant persona as a result of decades of 
being a criminal in the eyes of society. However, the biggest driver for me was the 
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belief  that the drug laws do not work. They do not prevent drug use, they actively 
create much of the harm they purport to prevent, and they are an infringement on 
our cognitive liberty to alter our own consciousness (Center for Cognitive Liberty 
and Ethics (CCL), 2004). Furthermore, as I became more involved in the drug 
policy debate, it was evident that it was not only drug consumers that felt they 
did not work. By 2014, there had been two significant independent reports on 
UK drug policy and its failure (The Royal Society for the encouragement of Arts 
Manufactures and Commerce (RSA), 2008; UKPDC, 2012). I was therefore pas-
sionate about exploring why, in the face of national and international evidence, 
drug policy was not changing in the direction being put forward.
I initially set out to explore the link between evidence and policy. I set up the 
Scottish Drug Policy Conversations (SDPC) in order to explore this link, and 
to provide a space for different policy actors to engage with a wider stakeholder 
group, including drug consumers. It was through this group, and the networks 
I made as a result, that the focus of the research changed. I became involved in 
different policy advisory groups, and through this began to experience the differ-
ent ways in which people are treated depending on their narrative of involvement. 
As a woman who uses drugs and has used many different drugs – both problem-
atically and non-problematically – and now a professional, I found myself  strad-
dling many different personas in order to engage at different levels.
This chapter explores this engagement in order to explore what the barriers 
are for participation in drug policy. In doing so, critical drug theory emerges as 
a potential framework to challenge these barriers. It starts by introducing the 
concept of critical drug theory, a concept which is not new but has yet to be devel-
oped in-depth by the critical theory literature, or named as such. It then moves 
onto my participation in three different policy groups, exploring how easy or dif-
ficult it was to connect with policymakers from each group and my experience 
of participation. Finally, I set out the typography of participation; the different 
kinds of drug consumers and their perceived legitimacy in the policy process, 
which emerged from my engagement.
Critical Drug Theory
Critical drug theory is a theoretical framework that challenges the assumption 
that drug use inevitably causes harm. It asserts that drug use is a social phenom-
enon, and the cultural framing of drug use is a result of systemic narratives that 
have been used to justify policies and practices which disproportionately impact 
those whose ethnicity, social class, gender, religious, ideological and political 
viewpoints do not fit into the dominant narrative. It contends that drug policy is 
an oppressive framework that seeks to de-legitimise and stigmatise these groups, 
and that the narratives of drug harm and the medico/legal structures which sur-
round drug use mean that evidence and participation are focussed on a small 
section of the drug-using population, namely problem drug use.
The focus on problem drug use has resulted in a focus on certain kinds of 
drug consumption, and a policy strategy to match that: recovery. As a result, only 
certain stakeholder views are taken into consideration when participation is being 
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designed at an institutional level, and only certain discourse is considered legiti-
mate. During my research, I separated these stakeholder engagements into four 
narratives: the professional, the sick, the recovered and the happy drug consumer. 
The legitimacy of these stakeholders is dependent on how they are involved and 
at what stage of the process. It will come as no surprise that the happy drug 
consumer is never invited to engage, and is in most instances not considered a 
legitimate voice.
Engaging with Policy: A Participant’s Journey
I engaged with three different policy groups over the course of several years, each 
one representing a different aspect of drug use and participation. The first group 
I was engaged with and helped set up was the SDPC, a multi-stakeholder group 
with the aim of bringing different voices to the policy table to discuss drug policy 
reform.
The setting up of SDPC provides an insight into how non-traditional struc-
tures (independent from government funding, a broad range of stakeholders and 
the use of deliberative engagement methods) can participate in the policy arena: 
we were taken seriously because our participants were viewed as ‘legitimate’, and 
the way in which we engaged was non-confrontational. Our participants were 
pooled from a cross-section of stakeholders and included many of the ‘same 
old faces’. Yet there were many non-traditional participants. As the convenor of 
SDPC, and a PhD candidate with professional experience in the public sector, 
I was able to approach senior figures in a range of institutional settings and be 
taken seriously. My own drug-using history was not known, and I was therefore 
considered an ‘objective’ broker between stakeholders. Generally speaking, I had 
little difficulty accessing policymakers and associated advisers and developed a 
personal relationship with members of the policy unit that enabled me to feed-
back the outcomes of SDPC, in the hope they would be used to help shape policy. 
Maintaining this relationship was more challenging.
As my personal drug use became more evident (through my own disclosure) 
my objective persona began to be questioned. Although the impact was subtle, 
and difficult to quantify, the involvement of institutional actors such as the police 
and the policy units started to become more difficult, and I found myself  being 
slowly shut out. This involved ignoring emails and requests for participation, and 
a general arm’s length behaviour when I met with institutional actors at vari-
ous events. This became clearer through my involvement with the second policy 
group, the Medicinal Cannabis Reform Scotland group (MCRS).
I became involved with the campaign leader after liking a Facebook page 
set up to support the first meeting held by MCRS at the Scottish Parliament. 
They had managed to get several members of  the Scottish Parliament and other 
interested parties to a meeting to discuss the movement towards a medicinal 
cannabis framework in Scotland, and I was impressed. I contacted her and sug-
gested she become involved in SDPC, and she attended the SDPC session on 
cannabis. However, it became apparent that the best role for her was running 
the MCRS group and building momentum for that campaign. The campaign 
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leader is a woman with fire, and she is doing it her way, which aggravates some 
people, alienates others, but in the end appears to get things done. She organ-
ised the first meeting, and I helped her set up the subsequent ones by connect-
ing her with relevant institutional actors such as the Substance Misuse Unit, 
Police Scotland and the Crown Office and Procurator Fiscal Service. My role 
within this process provided the academic position, highlighting the legal and 
practical hurdles that needed to be overcome, and providing a link between the 
different stakeholders involved by chairing the meetings using SDPC princi-
ples of  respectful dialogue. In addition, I identify as a cannabis user in both 
recreational and therapeutic capacities as a sleep aid and topical eczema treat-
ment. This meant my persona in this process straddled both the professional, 
the happy and the sick drug user, terms that will be explored below.
Engagement with institutional actors was difficult from the start. Institutions 
like things to be done through their own protocols, and when stakeholders do not 
behave in the way they should, they are shut out. Stakeholders are expected to 
defer to authority, and when they do not they are considered troublemakers. The 
problem with this viewpoint is that most drug-using stakeholders are passionate 
about their topic, because it affects their lives so immediately: they are literally 
dying as a result of policy. Therefore, to expect calm and rational responses to 
institutional hurdles and barriers is unreasonable. I attempted to act as a broker 
between the MCRS and institutions such as the police and government, but it 
became clear that they were not keen to engage on the issue of medicinal cannabis 
and the user group. Unlike the SDPC, which was seen as a neutral space, engage-
ment with MCRS was viewed as activism and lobbying.
As the hurdles increased and the frustration of those involved in MCRS inten-
sified, my own ability to directly engage with the institutions became increasingly 
difficult. My professional identity became unstuck and I began to be viewed as a 
stakeholder, and therefore someone with a vested interest in the outcomes. This 
experience is contrasted with the final group I was involved in, the Lived and 
Living Experience Executive group (LLEEG).
The LLEEG was set up by the Scottish Government’s drug policy advisory 
group Partnership for Action in Drugs (PADS, since disbanded) to provide a 
pathway for the voices of people who have ‘lived and living (current)’ experience 
of problematic drug use. The term ‘lived experience’ was initially used to describe 
someone with experiential knowledge of drug treatment and recovery services. 
During the course of its development, it was acknowledged that people who cur-
rently use drugs should also be involved in the process, and the terminology was 
expanded to ‘lived and living’. I was part of the first LLEEG meeting that started 
to ‘disrupt’ this term and my reflections on this specific point are as follows:
I found the process very moving – in regards to who is the drug 
user in this narrative it is most definitely the reformed user – those 
who have gone through the recovery process and are now ‘clean’. 
Yet, at the same time there was a recognition that there are voices 
missing from the conversation – that of the living drug user (i.e. 
those who still use drugs and are not interested in stopping).
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Even with the awareness that the living experience is missing, there 
seemed to be an unwillingness to properly address the fact that we 
are only focusing on those whose drug use appears to have caused 
a lot of harm, to themselves and their families. When I tried to get 
clarification on whether they mean all drug users I was met with 
nods of agreement, but a silent feeling that I was trying to bang a 
drum for something that was not worth the time. (PADS LLEEG, 
Bring Your Voice, June 2017)
My attempt to get clarification on the exact kind of living experience is reflec-
tive of my personal agenda. I have found that there is general agreement that 
Scottish drug policy is directed towards those that appear to cause the most harm, 
and this is logical. The problem lies in the fact that drug policy, both reserved and 
devolved (criminal legislation is reserved to the UK Government), affects all drug 
users. As a person who has used drugs for decades, and interacted with many 
drug-using communities, I have seen and experienced this.
In this group, I engaged as a woman with lived experience of problem drug use. 
This experience came from being in a relationship with a man who was dependent 
on heroin, and who ultimately died as a result of his drug use. I represented the fam-
ily member experience. However, I also wanted to engage as someone who had living 
experience of drug use, as a result of my recreational and medicinal use of cannabis, 
and occasional use of other drugs such as 3,4-Methyl enedioxy methamphetamine 
(MDMA), psilocybin and cocaine. I found that when I relayed my experiences of 
problem drug use, my engagement and stories were given validation. However, when 
I tried to engage as a recreational current user, they were not. Once again it was sub-
tle. It was not that I was silenced, but that the focus of the group was on drug harm, 
and therefore there was no space to talk about other kinds of drug use or drug users.
A final important note on this group: it was set up to provide pathways for 
the lived and living voice to be heard at the agenda-setting stage, specifically by 
choosing several representatives to sit on the executive committee of PADS. This, 
however, never happened. The group met three times and was then disbanded, as 
was PADS. What impact the group had on influencing policy is unknown, except 
for the inclusion of ‘living experience’ in the title, no feedback was ever commu-
nicated to the group, or evidenced by policy shifts as a result of their discussions. 
The result was a lack of trust of the Scottish government’s commitment to engage 
with the lived and living experience voice.
Typography of Drug User Participation
Through my involvement with these groups I began to see a typography of drug 
user participation, ranging from the legitimate to the illegitimate.
The Recovered/Recovering Drug Users: Legitimate
These users are people who are either in the recovery treatment system, or have 
recovered and are ‘drug free’ (or at least illicit drug free). People in this community 
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are predominantly in recovery from opiates, alcohol and cocaine, although the 
term covers all behaviours considered to cause dependence (one of my interview-
ees identified as being in recovery from an eating disorder). They are the main 
staple of drug policy engagement and are considered important stakeholders in 
policy development.
The recovery story has been part of Scottish drug policy since the 2008 ‘Road 
to Recovery’ (Scottish Government, 2008) strategy, and this has informed much 
of the participation work going forward. However, as one senior civil servant 
responsible for drug policy at the time commented:
I think the other thing that was interesting to me, and hadn’t really 
been so [... as I] hadn’t really had to think about it, was the number 
of people involved in this world that had actually been impacted 
by those issues themselves. So quite a lot of people declaring early 
on to me that they were in recovery and it became like a … it was 
almost like they were more worthy than other people because of 
their lived experience. (Senior Civil Servant, interview, 2016)
I experienced the same when engaging with groups, particularly with the 
LLEEG. The legitimate drug consumer was one who had stopped using drugs 
and was now able to present their experience to the group. They used their expe-
riences, sometimes from decades before, as their identity within the groups, yet 
challenged those of us who attempted to broaden out the narrative to include 
different kinds of drug users. As we saw, the lived experience expanded to include 
living experience, yet I only came across a handful of people within the group 
who identified with the living element, and those who did were either parents of 
children currently using drugs problematically, or were topping up their prescrip-
tion with street drugs.
The Sick Drug Users: Sometimes Legitimate
The sick user is only legitimate in one context: the engagement of problematic 
drug users. The sick user is one who is currently using drugs problematically and 
may not want to stop, but needs to be engaged in order to provide pathways for 
recovery when they want it. In many areas drug dependency is considered a dis-
ease of the mind, and the narrative goes ‘they are sick and need our help to get 
better’ (off  drugs).
However, in a different context the sick user has less legitimacy. In the con-
text of using cannabis, psychedelics or MDMA, all drugs that have recently been 
shown to help in various physical and mental illness (see further Beckley Foun-
dation, MAPS and Drug Science), users are not engaged with pro-actively, and 
in many cases engagement is made intentionally difficult. My experience of try-
ing to engage policymakers and institutions responsible for patient engagement, 
such as the MCRS, was difficult when I was representing the medicinal cannabis 
user. Indeed, my involvement with this group, as seen above, resulted in my own 
legitimacy being questioned, and my persona of professional and objective policy 
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expert became one of drug user lobbyist. As a result, my ability to access institu-
tional policymakers and engagements was reduced.
The Professional Drug User: Sometimes Legitimate
The professional drug user is hard to find because of the stigma associated with 
drug use. In general, professionals (and by this I mean individuals who are part 
of an institutional profession such as academia, 3rd sector, public bodies or are in 
the process of creating a professional career) do not disclose drug use as to do so 
would risk their career development. A good illustration of the consequences of 
drug use being discovered is the following story from one of my interviewees:
An incident happened and a doctor overdosed on heroin in this 
hospital, and it was really horrible because it was one of  these 
things were his wife phoned up and said my husband’s not come 
home, does anyone know where he is, that kind of  thing, and 
he was found in a toilet. He was alive! And of  course, somehow 
these things always seem to get on the front page of  the Daily 
Record (tabloid newspaper) you know [laughs] so names, people 
get named and all that. So it was one of  these organisational 
things that happened, ‘oh my god’, you know. And the organisa-
tion just decided they were gonna have this guy for breakfast, so 
they were gonna take him down a very very unpleasant discipli-
nary route.
And as the local addictions specialist I was asked to give my opin-
ion with regard to this guy. And of course I gave the opinion which 
was he has a…without going into all the details there were many 
reasons why this had happened, it was all very understandable, it 
was all very explainable. And, when you’re faced with people not 
being able to perform at work, in the NHS, you take them down 
one of two routes: it’s either a disciplinary route, or it’s a – as we 
would call it – a sick doctor route. I advised we should take him 
down the sick doctor route.
Wow. Light the torch paper, stand well back. I was in hearings, and 
it was … so they were trying to say you can’t possibly be a doctor 
and have had a drug problem. So, because people can’t … what 
they were really saying was people can’t not have a drug problem 
any more, he’s a heroin addict, he’s going to take people’s drugs 
and use them for himself  … that monster! So, it was really interest-
ing ‘cause I had to put … you know it was one of those, you know, 
when you’ve got a career, you actually have to go ‘hmmmm, okay, 
I’m gonna step over here now’, and you have to go nut (no), this is 
my position, here’s my position. (Addictions Specialist and senior 
government advisor, interview, 2016)
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This story gives us insight into the professional implications of drug use, and 
the responses from the institution. What the narrator is telling us is that the insti-
tution was not able to respond compassionately, because they did not understand 
the complexity of drug use. Even with the advice of the specialist, they were una-
ble to comprehend how someone can continue to be a professional once they have 
used drugs. While the potential for him to be considered a ‘sick’ doctor (legiti-
mate) existed, this was not an option because of the publicity surrounding the 
case. From this, and many other anecdotes I came across, it has become apparent 
that there is a dichotomy between the professional and the drug user.
I experienced this dichotomy, and I hope to have gone some way to challeng-
ing it. My involvement in the policy process came about through SDPC, and my 
persona, as mentioned above, was one of an academic and professional. However, 
through the course of the engagements I became more vocal about my own drug 
use, thereby mixing my engagement as a professional and a drug user. The first 
time I informed a member of a larger institution that I used drugs I was met with 
that slightly startled flickering eye movement. I could see them processing this 
information and trying to make it match with their previous impression of me. It 
was a risky move, and I was advised against by several peers, but I felt I could not 
continue to engage and speak about drug users as if  they were somehow ‘other’ to 
me. My relationship with institutional representatives did not change much after 
my disclosure, at least not at first, but I was still constrained in how I could par-
ticipate, through the avenues described above. I have found that the policy identity 
that was cultivated as a result of disclosing lived experience, was a ‘lived experi-
ence and professional policy expert’ persona, both of whom are legitimate in my 
typology of participation. However, if  I start engaging with the ‘happy drug user’ 
persona, I am not afforded the same weight in policy discussions.
These two stories show that in some contexts the professional drug user is con-
sidered a legitimate participant, although professionals who use drugs are gener-
ally not considered legitimate stakeholders in the process, or indeed legitimate 
professionals.
The Happy Drug User: Never Legitimate
The happy drug user is hardly seen in drug policy. The idea that someone 
takes drugs pleasure, and continues to be happy despite drug use, is not spo-
ken about, and those who do are silenced. This silencing is subtle. Because of 
the focus on harm, all initiatives, meetings, engagements and documents come 
from this paradigm. Discussions on the pleasure of  drugs are silenced by the 
focus on harm, and those who challenge this are considered to be indulging in 
personal agendas.
Yet, it’s not so much that the happy drug user is ignored completely, but the 
tactic of sidestepping is practiced in order to silence the narrative. The concept of 
the non-problematic drug user is set out in the 2008 drug strategy (Scottish Gov-
ernment, 2008) where they define three broad categories: experimenters, regular 
users and problem users. It is the final category that drug policy appears to focus 
on. In private discussions of drug use between the drug policy communities, it is 
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commonly accepted that the majority of drug users consume drugs with minimal 
harm, and do so for enjoyment. Yet, this acknowledgement is not acted upon 
once it has been expressed. This sidestepping sits alongside the concept of ‘moral 
sidestepping’, developed by Alex Stevens (2019).
In his article, Stevens (2019) examines why it is that despite recommendations 
from the Advisory Council on the Misuse of Drugs (ACMD) and other institu-
tional bodies, initiatives that would reduce harm, such as drug consumption rooms 
and heroin-assisted treatment, are not being implemented. Stevens analysed par-
liamentary documents from 2016 to 2018 and found that there is a practice of 
moral sidestepping – that is, the acknowledgement of the evidence supporting 
the initiative (consumption rooms etc.) and a side step by stating their own moral 
belief  that taking drugs should be strongly condemned. The result is inaction, 
based on the implication that to act is morally wrong (in a puritanical Chris-
tian sense) (Stevens, 2019). In Scotland, the excuse is that criminal sanctions are 
reserved, allowing policymakers to sidestep the tricky questions without address-
ing the issue head-on. I call this ‘constitutional sidestepping’. By acknowledging 
but ignoring, a form of this tactic is successfully employed to dismiss the views of 
those who are not considered legitimate stakeholders in drug policy discussions.
While policymakers use tactics such as moral sidestepping and silencing to 
prevent broader discussions of drug use, another important factor for non- 
engagement of ‘happy drug users’ in the policy process is the criminal nature 
of the activity. Only those who are considered problematic users, and therefore 
excused from their drug-taking behaviour as a result of their lack of agency 
(addiction brought on by poverty/mental health/trauma and are unable to stop), 
are considered to be the legitimate focus of participation, and only marginally 
at this. To suggest that the wider drug-using population, the health worker that 
smokes joints, the nursery teacher that takes a bit of cocaine every now and then, 
the postman who goes to annual raves or the artist who indulges in lysergic acid 
diethylamide (LSD), are every bit as legitimate in the policy process as those who 
have serious problematic drug use, is to suggest that drug use per se is not the 
problem. This was apparent from the SDPC engagements where many partici-
pants who had used drugs, in the past and currently, did not feel able to openly 
admit it beyond the safety of a group governed by Chatham House Rules.1 The 
concept of a ‘coming out’ day was mooted, but once again many felt unable to put 
their careers and professional persona on the line. Indeed, one professional who 
is also a regular heroin user commented that if  they came out, there was a very 
strong possibility the police would use their phone to get to their dealer. This is a 
very real concern and one that exists in the medicinal cannabis community too. 
The campaign leader for MCRS openly grows her own cannabis plants for her 
medicine. The police know it, because through our engagement with the police she 
has spoken about it. However, this has left her vulnerable to criminal prosecutions 
should the police decide to use this information to make another ‘drugs bust’.
1A form of confidentiality developed by Chatham House. See further https://www.
chathamhouse.org/chatham-house-rule.
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Final Thoughts
As a result of policy being focussed on drug-related harm, participation in pol-
icy is restricted to certain channels where the government feel they can be most 
effective. They, therefore, focus on the harms stemming from problematic use and 
participatory processes to engage this affected community are developed along 
these lines.
Critical drug theory seeks to challenge this focus by highlighting the silence 
around drug use for pleasure and self-medication, and the oppression of certain 
groups in society. It is a work in progress and will need to be developed and tested 
in order for it to become part of the critical theory landscape. However, it is 
grounded in critical thought with the underlying premise that the foundations of 
drug policy, both national and international, are based on ideological reasoning 
that is often used to suppress and silence those who seek to challenge the status 
quo. Subjecting policies to critique and critical evaluation, such as research into 
the impact drug laws have on individuals and society (as opposed to the impact 
drug use has), should be advocated, along with public engagement on the com-
plexity of drug use and harm.
Yet, because the dominant narrative surrounding drug use is one of totemic 
toughness (Stevens, 2009), and people who use drugs are viewed as problems to 
be dealt with as a result of the harm stemming from their use, those whose liveli-
hoods would be put at risk if  they were considered to lack personal control and 
agency will not raise their heads above the parapet. This is the fundamental prob-
lem facing public participation in drug policy-making; only those willing to take 
the risk, or who have nothing to lose by ‘coming out’, will be engaged at this stage. 
These drug consumers are invariably already part of the system because they 
have had to identify as a drug user in order to access medical and social support. 
The focus on harmful drug use masks the widespread use of drugs by a variety of 
different communities, and prevents honest dialogue about the impact drug use 
and drug policy has on society as a whole.
